from The American Heritage® Dictionary of the English Language, 4th Edition
- n. The blocking of a blood vessel by a blood clot dislodged from its site of origin.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. An embolism caused by a blood clot carried in the bloodstream from its place of origin
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. occlusion of a blood vessel by an embolus that has broken away from a thrombus
Although previous studies have linked hypertensive disorders during pregnancy -- which occur in 5\% to 7\% of all pregnancies -- with risk of death, ischemic heart disease, and stroke, less is known about their relationship with other outcomes, such as thromboembolism and diabetes, according to Dr. Lykke.
In one of the other studies, called Adopt, apixiban, an anticoagulant in the same class as rivaroxaban that is being developed by Pfizer Inc. and Bristol-Myers Squibb, failed to outperform an older drug called enoxaparin in preventing venous thromboembolism, or VTE, in patients who had extended hospital stays for other conditions.
Xarelto is currently approved in the U.S. as a short-term treatment to prevent certain blood clots, known as venous thromboembolism, or VTE, in people undergoing knee- and hip-replacement surgery.
Eliquis already has received European regulatory approval as a treatment to prevent certain blood clots, known as venous thromboembolism, in people undergoing knee- and hip-replacement surgery.
I would agree that in younger women there remains a concern about thromboembolism and stroke, but the use of transdermal lower dose preparations may mitigate much of this risk.
Hormone therapy among women aged 50 through 59 years in the WHI trials tended to have more favorable effects on CHD rates than in older women, but even if this finding is confirmed, the concerns about increased risk of stroke, venous thromboembolism, and breast or endometrial cancer remain.
On Friday, J&J and Bayer said the FDA approved Xarelto to prevent certain blood clots, known as venous thromboembolism, or VTE, in people undergoing knee- and hip-replacement surgery.
Bayer HealthCare already markets its factor Xa inhibitor, Xarelto, for vein clotting, or venous thromboembolism.
Dr. Robert Harrington of Duke Clinical Research Institute said recent Phase III clinical trials of apixaban have shown promising results in patients with venous thromboembolism and atrial fibrillation.
Acute coronary syndrome involves the coronary arteries, while venous thromboembolism involves arteries in the lungs and atrial fibrillation is an abnormal heart rhythm involving the two upper chambers of the heart.
Wordnik is becoming a not-for-profit! Read our announcement here.